Sprout Pharmaceuticals sprouts by 440 percent with new drug offering for women
RALEIGH, N.C. — Sprout Pharmaceuticals has grown by about 440 percent since August when it received the first ever FDA approval for a drug to treat a sexual disorder in women. The company now has a sales force of 150 spread throughout the country and another 40 workers in the home office in Raleigh.
It was acquired by Valeant Pharmaceuticals for an all-cash deal worth $1 billion. It increased its workforce from 34 to 200 following FDA approval of Addyi. The company will not sell direct-to-consumer. Instead the sales force will talk to doctors and encourage them to consider Addyi as a possible treatment for Hypoactive Sexual Desire Disorder, which causes low libido in women.
In addition to increasing the sales force, the company will continue studying Addyi in order to better understand how it works in patients using the drug outside the strict controls of a clinical trial.
Source: Triangle Business Journal